Novocol Pharmaceutical plans CAD$54m expansion
Five-year project wins support of CAD$10m from Ontario government
Novocol Pharmaceutical of Canada, a manufacturer of dental anaesthesia and related products, is investing more than CAD$54m in expanding and modernising its facility in Cambridge, Ontario.
The Ontario government is contributing CAD$10m to the five-year project that will help the company diversify and develop new infection control products, increasing its global competitiveness.
The modernisation will include converting an outdated production line into an r&d centre.
Novocol Pharmaceutical and its affiliated owner, Septodont of France, are world leaders in the production of dental anaesthetic cartridges. Novocol controls a large portion of the US market, through its own brands, or the manufacture of other brands, and private label products.
Kent Chiu, president of Septodont North America, said: ‘On the highly competitive global stage, modernisation is no longer an option used for getting ahead of the competition; it’s an essential just to stay in business.
‘Ontario’s support to help us invest in advanced r&d and innovation is what it takes to get us to the next level and to help create local jobs and give back to the community what has helped make this company such a success.’
